Program
Alprazolam
Also written as “Alprazolam Extended-Release 3 mg Tablets”, “Staccato alprazolam” and “alprazolam XR”.
Its studies are mostly in Anxiety Disorders · Panic Disorder · Seizures · Epilepsy · Asthma, led by 6 companies.
Drug pageAlprazolam: every studyMany companies study it; this page follows only the 26 they lead. All 62 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 120 open or running | phase 4since Mar 5, 2008 | Oct 26, 2005 | none ahead |
| Teva Pharmaceutical Industriesits history only | 60 open or running | phase 1since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 1since Nov 28, 2012 | Nov 28, 2012 | none ahead |
| Novartisits history only | 20 open or running | phase 1since Jun 2, 2009 | Jun 2, 2009 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 20 open or running | phase 1since Apr 8, 2009 | Apr 8, 2009 | none ahead |
| Nova Pneumaits history only | 10 open or running | phase 1since Jan 17, 2008 | Jan 17, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viatris only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 26, 2005First study: phase 2 study in Dental AnxietyFirst studyNCT00245609 · 90 enrolled · Germany, United Kingdom
- Mar 5, 20083 phase 4 studies in Panic DisorderNCT00635531, NCT00635076, NCT00634790
- Mar 28, 20083 phase 1 studies in HealthyNCT00647894, NCT00650299, NCT00647634
- Dec 16, 2008Phase 1 study in PharmacokineticsNCT00810316 · 24 enrolled · Mexico
- Mar 10, 2009Phase 1 study in HealthyNCT00860119 · 23 enrolled · India
- Jan 7, 2010Phase 1 study in HealthyNCT01046162
- Apr 5, 2011Phase 1 study in Healthy SubjectsNCT01330472 · 16 enrolled · Singapore
- Aug 17, 2026Phase 4 study in Healthy Non-dependent, Recreational Sedative UsersNCT07777965 · 44 enrolled · United States
TargetBeta
“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule
Other programs on the same 16 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Midazolamrule | Eli Lilly | phase 4 | 97 |
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 36 |
| brexanolonerule | Supernus Pharmaceuticals | phase 4 | 14 |
| Diazepamrule | Acorda Therapeutics | phase 3 | 9 |
Studies
All 12 Viatris leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07777965Healthy Non-dependent, Recreational Sedative Users · United States | 4 | Completed | Aug 31, 2026 | 44 |
| NCT01330472Healthy Subjects · Singapore | 1 | Completed | Jun 2011 | 16 |
| NCT01046162Healthy | 1 | Withdrawn | Jul 22, 2010 | 0 |
| NCT00860119Healthy · India | 1 | Completed | Oct 2009 | 23 |
| NCT00810316Pharmacokinetics · Mexico | 1 | Completed | Nov 2008 | 24 |
| NCT00650299Healthy · United States | 1 | Completed | Aug 2004 | 21 |
| NCT00647634Healthy · United States | 1 | Completed | Aug 2004 | 21 |
| NCT00647894Healthy · United States | 1 | Completed | Jan 2005 | 24 |
| NCT00635531Panic Disorder · United States | 4 | Terminated | 16 | |
| NCT00635076Panic Disorder · United States | 4 | Terminated | 3 | |
| NCT00634790Panic Disorder · United States | 4 | Terminated | 49 | |
| NCT00245609Dental Anxiety · Germany, United Kingdom | 2 | Completed | 90 |
How it is read
Names in the registry
- “Alprazolam”, 10 entries
- “Alprazolam Extended-Release 3 mg Tablets”, 4 entries
- “Staccato alprazolam”, 3 entries
- “alprazolam XR”, 3 entries
- “Staccato Alprazolam”, 2 entries
Conditions, from the studies’ own filings
- Anxiety Disorders, 5 studies
- Panic Disorder, 3 studies
- Seizures, 2 studies
- Epilepsy, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.